![](/img/cover-not-exists.png)
Phase I study of an oral formulation of irinotecan administered daily for 14
Nadja E. Schoemaker, I. E. L. M. Kuppens, Wim W. Ten Bokkel Huinink, Patricia Lefebvre, Jos H. Beijnen, Sylvie Assadourian, Ger-Jan Sanderink, Jan H. M. SchellensVolume:
55
Language:
english
Pages:
8
DOI:
10.1007/s00280-004-0874-2
Date:
March, 2005
File:
PDF, 227 KB
english, 2005